World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
54
Citations
17652
World Ranking
3839
National Ranking
1760

Overview

Adrian Bot is affiliated with MannKind Corporation based in the United States. Their research primarily spans the field of Medicine, with a strong concentration in Oncology and Immunology. Their work also encompasses Molecular Biology, Genetics, and Electrical and Electronic Engineering.

The scientist's research contributions focus heavily on CAR-T cell therapy, immunotherapy, and related immune responses. Key topics addressed in their publications include:

  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Virus-based gene therapy research
  • Integrated Circuits and Semiconductor Failure Analysis
  • Advancements in Semiconductor Devices and Circuit Design
  • Lymphoma Diagnosis and Treatment
  • Nanowire Synthesis and Applications

Adrian Bot has co-authored publications frequently with several researchers, including:

  • John M. Rossi
  • Sattva S. Neelapu
  • Caron A. Jacobson
  • Frederick L. Locke
  • Lazaros J. Lekakis

Their papers have appeared notably in specialized venues such as Blood, Journal of Clinical Oncology, Nature Medicine, Transplantation and Cellular Therapy, and Clinical Lymphoma Myeloma & Leukemia.

Selected recent papers authored or co-authored by Adrian Bot include:

  • Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma, 2020, Blood Advances
  • Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma, 2020, Nature Medicine
  • TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers, 2021, Nature Medicine
  • A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy, 2021, Cancer Discovery
  • KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results, 2021, Blood

Best Publications

  • Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

    Sattva S. Neelapu;Frederick L. Locke;Nancy L. Bartlett;Lazaros J. Lekakis

  • Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial

    Frederick L Locke;Armin Ghobadi;Caron A Jacobson;David B Miklos

  • Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

    Frederick L. Locke;Sattva S. Neelapu;Nancy L. Bartlett;Tanya Siddiqi

  • Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels

    James N. Kochenderfer;Robert P.T. Somerville;Tangying Lu;Victoria Shi

  • Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma.

    Frederick L. Locke;John M. Rossi;Sattva S. Neelapu;Caron A. Jacobson

  • Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL.

    John Rossi;Patrick Paczkowski;Yueh-Wei Shen;Kevin Morse

  • Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma

    Jennifer N Brudno;Norris Lam;Danielle Vanasse;Yueh-Wei Shen

  • TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers.

    Nisha B. Nagarsheth;Scott M. Norberg;Andrew L. Sinkoe;Sabina Adhikary

  • Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.

    James N. Kochenderfer;Robert P.T. Somerville;Tangying Lu;James C. Yang

  • Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma

    Unknown

  • Autoreactive CD4+ T Cells Protect from Autoimmune Diabetes via Bystander Suppression Using the IL-4/Stat6 Pathway

    Dirk Homann;Andreas Holz;Adrian Bot;Bryan Coon

  • Antigen kinetics determines immune reactivity.

    Pål Johansen;Tazio Storni;Lorna Rettig;Zhiyong Qiu

  • A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy

    Ranjan Upadhyay;Jonathan A. Boiarsky;Gvantsa Pantsulaia;Judit Svensson-Arvelund

  • Protective Role of Gamma Interferon during the Recall Response to Influenza Virus

    Adrian Bot;Simona Bot;Constantin A. Bona

  • KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.

    Bijal D Shah;Michael R Bishop;Olalekan O Oluwole;Aaron C Logan

  • Preliminary Results of Prophylactic Tocilizumab after Axicabtageneciloleucel (axi-cel; KTE-C19) Treatment for Patients with Refractory,Aggressive Non-Hodgkin Lymphoma (NHL)

    Frederick L. Locke;Sattva S. Neelapu;Nancy L. Bartlett;Lazaros J. Lekakis

  • CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel

    Vicki Plaks;John M. Rossi;Justin Chou;Linghua Wang

  • Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL

    Zachary J Roberts;Marc Better;Adrian Bot;Margo R Roberts

  • Plasmid Vaccination with Insulin B Chain Prevents Autoimmune Diabetes in Nonobese Diabetic Mice

    Adrian Bot;Dan Smith;Simona Bot;Anna Hughes

  • Direct intralymphatic injection of peptide vaccines enhances immunogenicity.

    P. Johansen;A. C. Häffner;F. Koch;K. Zepter

  • Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract.

    Adrian I. Bot;Thomas E. Tarara;Dan J. Smith;Simona R. Bot

  • Particulate delivery systems and methods of use

    Adrian I. Bot;Thomas E. Tarara;Jeffry G. Weers;Alexey Kabalnov

  • Noncoding RNA danger motifs bridge innate and adaptive immunity and are potent adjuvants for vaccination

    Lilin Wang;Dan Smith;Simona Bot;Luis Dellamary

Frequent Co-Authors

Constantin A. Bona
Constantin A. Bona Icahn School of Medicine at Mount Sinai
John J. Rossi
John J. Rossi City Of Hope National Medical Center
James N. Kochenderfer
James N. Kochenderfer National Institutes of Health
Steven A. Rosenberg
Steven A. Rosenberg National Institutes of Health
Nancy L. Bartlett
Nancy L. Bartlett Washington University in St. Louis
Thomas M. Kündig
Thomas M. Kündig University of Zurich
Matthias von Herrath
Matthias von Herrath Diabetes Research Institute Foundation
Ian W. Flinn
Ian W. Flinn Sarah Cannon Research Institute
Antoni Ribas
Antoni Ribas University of California, Los Angeles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in expanding their career options after a foundation in immunology, exploring online nursing degrees can be a strategic move. Programs like online absn programs for non nurses provide accelerated pathways for individuals with non-nursing backgrounds to quickly enter the healthcare field.

Nurse practitioners specializing in family care can advance their skills by transitioning to acute care through focused programs. Resources on how to fnp to acnp transitions offer guidance for making this critical career shift successfully.

Accelerated educational options are also available for those looking to become nurse practitioners efficiently. Finding the right accelerated fnp program allows students to balance rigorous study with personal commitments.

Understanding the job market is equally important. Salaries can vary widely depending on location, making resources that detail the dnp salary by state valuable for planning your career path and geographic preferences.

Best Scientists Citing Adrian Bot

Trending Scientists